Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Development for anthrax and MRSA treatment
Compound found with ability to kill problem bacteria

The discovery of a new chemical compound produced by a microorganism has offered hope for the future treatment of anthrax and methicillin-resistant staphylococcus aureus (MRSA).

A scientist from the Scripps Institution of Oceanology at the University of California, San Diego, first collected the microorganism in 2012, from sediments close to the Santa Barbara shore.

Following the finding, a San Diego-based company worked in conjunction with the team from the university's Center for Marine Biotechnology and Biomedicine, to decipher the unusual structure of the compound's molecules.

The team then discovered that the unusual compound, which they named anthracimycin, has the power to kill bacteria that causes anthrax and MRSA.

As a result, it is hoped that the finding will one day lead to the development of a new antibiotic drug.

"The real importance if this work is the fact that anthracimycin has a new and unique chemical structure," said William Fenical, professor of oceanography and pharmaceutical science, who led the team.

"The discovery of truly new antibiotic compounds is compounds is quite rare. This discovery adds to many previous discoveries, which show that marine bacteria are genetically and chemically unique."

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.